STOCK TITAN

BIOC - BIOC STOCK NEWS

Welcome to our dedicated page for BIOC news (Ticker: BIOC), a resource for investors and traders seeking the latest updates and insights on BIOC stock.

Biocept, Inc. (BIOC) pioneers molecular diagnostics for cancer management through its proprietary Target Selector™ technology. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s advancements in liquid biopsy solutions and oncology research.

Access real-time announcements including financial results, strategic partnerships, and clinical validation studies. Our curated collection ensures efficient tracking of Biocept’s progress in developing non-invasive diagnostic tools that inform treatment decisions and improve patient care pathways.

Key updates cover regulatory milestones, technology enhancements, and collaborations with biopharmaceutical partners. Bookmark this page for direct access to primary source materials, including earnings calls analysis and product launch details, all organized for informed decision-making.

Rhea-AI Summary
Biocept announces full enrollment of subjects in feasibility phase of FORESEE clinical trial for CNSide assay
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
-
Rhea-AI Summary
Biocept signs non-exclusive licensing agreement for CNSide with Plus Therapeutics for clinical trial on targeted radiotherapeutic. Plus will pay Biocept $150,000 upfront fee in stock and $6,000 per CSF tumor cell enumeration analysis. Positive validation of CNSide's clinical utility and potential future agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Biocept to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.89%
Tags
conferences
Rhea-AI Summary
Biocept, Inc. will hold a conference call on August 30, 2023, to provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
-
Rhea-AI Summary
Biocept, Inc. (Nasdaq: BIOC) reports financial results for the second quarter of 2023, with net revenues at $0.6 million and a net loss of $3.6 million. The company is focused on establishing its proprietary cerebrospinal fluid assay CNSide™ as standard of care and is making progress in the FORESEE clinical trial. Biocept also plans to provide further evidence of CNSide’s clinical utility through publication in peer-reviewed medical journals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
-
Rhea-AI Summary
Biocept's CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 SNO/ASCO CNS Cancer Conference. The assay showed promise in detecting leptomeningeal metastasis (LM) and improving treatment decisions. HER2 amplification in the CSF was found in a significant number of patients with LM, suggesting potential targeted therapies. Circulating tumor cell (CTC) analysis using CNSide provided superior sensitivity in detecting leptomeningeal carcinomatosis (LMC) compared to traditional cytology, allowing for earlier detection and treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
Rhea-AI Summary
Biocept, Inc. announces the passing of M. Faye Wilson, Board Chair. Wilson was a respected business executive and philanthropist known for her advocacy for women's rights and equality in the workplace. The company expresses condolences and appoints new Board Chair and Vice Chair.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.46%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.27%
Tags
none
-
Rhea-AI Summary
Biocept to present at Maxim Group Virtual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
BIOC

Nasdaq:BIOC

BIOC Rankings

BIOC Stock Data

Medical Laboratories
Health Care and Social Assistance
Link
US
San Diego